20 March 2014 EMA/CHMP/219148/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Folcepri International non-proprietary name: etarfolatide Procedure No.: EMEA/H/C/002570/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. This AR reflects the CHMP opinion on 20 March 2014, which originally recommended to approve this medicine. The recommendation was conditional to the results of the on-going confirmatory study EC-FV-06. Before the marketing authorisation was granted by the EC, the results of this study became available and did not support the initial recommendation. Subsequently, the company decided to withdraw the application and not to pursue any longer the authorisation for marketing this product. The current report does not include the latest results of this study as the withdrawal of the application did not allow for the CHMP to revise its opinion in light of the new data. For further information please refer to the Q&A which followed the company’s withdrawal of the application. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5505 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ...................................................................................... 6 1.2. Manufacturers ...................................................................................................... 8 1.3. Steps taken for the assessment of the product ......................................................... 8 2. Scientific discussion ................................................................................ 9 2.1. Introduction......................................................................................................... 9 2.2. Quality aspects .................................................................................................. 12 2.2.1. Introduction .................................................................................................... 12 2.2.2. Active Substance ............................................................................................. 12 2.2.3. Finished Medicinal Product ................................................................................ 14 2.2.4. Discussion on chemical, pharmaceutical and biological aspects .............................. 15 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects ...................... 15 2.2.6. Recommendation(s) for future quality development ............................................. 15 2.3. Non-clinical aspects ............................................................................................ 15 2.3.1. Introduction .................................................................................................... 15 2.3.2. Pharmacology ................................................................................................. 16 2.3.3. Pharmacokinetics............................................................................................. 19 2.3.4. Toxicology ...................................................................................................... 22 2.3.5. Ecotoxicity/environmental risk assessment ......................................................... 25 2.3.6. Discussion on non-clinical aspects...................................................................... 25 2.3.7. Conclusion on the non-clinical aspects ................................................................ 27 2.4. Clinical aspects .................................................................................................. 28 2.4.1. Introduction .................................................................................................... 28 2.4.2. Pharmacokinetics............................................................................................. 31 2.4.3. Pharmacodynamics .......................................................................................... 35 2.4.4. Discussion on clinical pharmacology ................................................................... 35 2.4.5. Conclusions on clinical pharmacology ................................................................. 37 2.5. Clinical efficacy .................................................................................................. 37 2.5.1. Dose response study ........................................................................................ 38 2.5.2. Exploratory studies .......................................................................................... 38 2.5.3. Main studies ................................................................................................... 42 2.5.4. Discussion on clinical efficacy ............................................................................ 67 2.5.5. Conclusions on the clinical efficacy ..................................................................... 72 2.6. Clinical safety .................................................................................................... 72 2.6.1. Discussion on clinical safety .............................................................................. 82 2.6.2. Conclusions on the clinical safety ....................................................................... 84 2.7. Pharmacovigilance .............................................................................................. 84 2.8. Risk Management Plan ........................................................................................ 84 2.9. User consultation ............................................................................................... 88 Assessment report EMA/CHMP/219148/2014 Page 2/93 3. Benefit-Risk Balance ............................................................................. 88 4. Recommendations ................................................................................. 91 Assessment report EMA/CHMP/219148/2014 Page 3/93 List of abbreviations 99mTc-EC20, Technetium-99m-EC20 etarfolatide-technetium-99m complex AE adverse event ALT alanine aminotransferase ANC absolute neutrophil count ASCO American Society of Clinical Oncology AST aspartate aminotransferase ATC Anatomic Therapeutic Chemical BSA body surface area BUN blood urea nitrogen CA-125 cancer antigen 125 CBC complete blood cell CI confidence interval CR complete response CRF case report form CT computed tomography CTCAE Common Terminology Criteria for Adverse Events DCR disease control rate DSMB data safety monitoring board EC20 folate-targeting imaging agent EC145 folic acid-desacetylvinblastine hydrazide conjugate ECOG Eastern Cooperative Oncology Group FDA Food and Drug Administration FIGO International Federation of Gynaecology and Obstetrics FR folate receptor GCP Good Clinical Practice G-CSF granulocyte colony-stimulating factor GGT gamma–glutamyl transferase GCIG Gynaecologic Cancer Intergroup GERD gastroesophageal reflux disease HR hazard ratio IA interim analysis IBW ideal body weight ICH International Conference on Harmonisation IE insufficient evaluation IEC independent ethics committee IM intramuscular IRB institutional review board IRF independent review facility ITT intent to treat IV intravenous, intravenously LD longest diameter LVEF left ventricular ejection fraction MedDRA Medical Dictionary for Regulatory Activities mITT intent to treat population of all measurable patients MRI magnetic resonance imaging MUGA multiple gated acquisition ORR objective response rate OS overall survival PD progressive disease PFS progression-free survival PLD pegylated liposomal doxorubicin PP per-protocol PROC platinum resistant ovarian cancer PR partial response Assessment report EMA/CHMP/219148/2014 Page 4/93 RBC red blood cell RECIST Response Evaluation Criteria in Solid Tumours RFC reduce folate carrier SAE serious adverse event SAP statistical analysis plan SD stable disease SOC system organ class SPECT single photon emission computed tomography TEAE treatment emergent adverse event ULN upper limit of normal WBC white blood cell WHO World Health Organization Assessment report EMA/CHMP/219148/2014 Page 5/93 1. Background information on the procedure 1.1. Submission of the dossier The applicant Endocyte Europe, B.V. submitted on 26 October 2012 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Folcepri, through the centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 18 October 2012. Folcepri was designated as an orphan medicinal product EU/3/12/1043 on 10 September 2012. Folcepri was designated as an orphan medicinal product in the following indication: Diagnosis of positive folate receptor status in ovarian cancer. The applicant applied for the following indication: This medical product is for diagnostic use only. After radiolabelling with sodium pertechnetate (99mTc) solution, Folcepri is indicated for single photon emission computed tomography (SPECT) imaging, in combination with CT or MRI, for the selection of adult patients for whom treatment with Vynfinit, a folate receptor (FR) targeted therapeutic, is being